| 89.775 0.575 (0.64%) | 10-28 11:51 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 105.99 |
1-year : | 123.8 |
| Resists | First : | 90.75 |
Second : | 105.99 |
| Pivot price | 79.57 |
|||
| Supports | First : | 78.35 |
Second : | 70.69 |
| MAs | MA(5) : | 79.87 |
MA(20) : | 78.63 |
| MA(100) : | 71.4 |
MA(250) : | 55.69 |
|
| MACD | MACD : | 1 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 45.8 |
D(3) : | 45.2  |
| RSI | RSI(14): 65 |
|||
| 52-week | High : | 90.75 | Low : | 36.56 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KNSA ] has closed Bollinger Bands are 25.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 76.52 - 77 | 77 - 77.34 |
| Low: | 69.62 - 70.19 | 70.19 - 70.59 |
| Close: | 72.22 - 73.07 | 73.07 - 73.67 |
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Wed, 28 Oct 2026
KNSA Maintained by Wedbush -- Price Target Raised to $102 - GuruFocus
Wed, 28 Oct 2026
KNSA Maintained by Wells Fargo -- Price Target Raised to $110 - GuruFocus
Tue, 27 Oct 2026
Kiniksa Pharmaceuticals International PLC (KNSA) (Q3 2026) Earnings Call Highlights: ARCALYST ... - Yahoo Finance
Tue, 27 Oct 2026
KNSA Stock Climbs As Traders Eye Leadership Shift And Q3 Call - Timothy Sykes
Tue, 27 Oct 2026
Kiniksa Pharmaceuticals International, plc Stock 12‑Month Price Target Raised to $99, Implies 36% Upside - TradingView
Tue, 27 Oct 2026
Kiniksa Pharmaceuticals International, plc 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:KNSA) 2026-10-27 - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 48 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 101.8 (%) |
| Shares Short | 3,780 (K) |
| Shares Short P.Month | 3,790 (K) |
| EPS | 0.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.39 |
| Profit Margin | 9.5 % |
| Operating Margin | 11.1 % |
| Return on Assets (ttm) | 8 % |
| Return on Equity (ttm) | 14 % |
| Qtrly Rev. Growth | 55.4 % |
| Gross Profit (p.s.) | 9.49 |
| Sales Per Share | 17.41 |
| EBITDA (p.s.) | 2.11 |
| Qtrly Earnings Growth | 30.3 % |
| Operating Cash Flow | 185 (M) |
| Levered Free Cash Flow | 126 (M) |
| PE Ratio | 90.1 |
| PEG Ratio | 0 |
| Price to Book value | 10.63 |
| Price to Sales | 5.12 |
| Price to Cash Flow | 23.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|